Search Results for: covid

Media Coverage – All

NEWSROOM Stay current with MiRXES Media Coverage Stay informed and keep abreast with our media news. 20 Apr 2022 科企爭奪人才戰 3招添勝 HKET – 疫情加速了科技融入医药学科研范畴,生物科技行业开始获得市场关注。专注于核糖核酸(RNA)科技的新加坡高生物科技企业「觅瑞」(MiRXES),自2014年起致力于研发疾病早诊技术与将其商业化。现时业务遍布香港、中国、日本、美国等45个国家及地区,故吸纳人才成为其首要挑战。 该企藉创造一个较人性化及较灵活的工作环境等3招,以招徕人才。 7 Apr 2022 Changing Lives through Biomarker Discovery InvestHK – MiRXES is a biotechnology company founded in 2014. It translates research discoveries to deliver early detection of multiple cancers using …

Media Coverage – All Read More »

Careers

CAREERS Join the MiRXES Team​ Be part of the team delivering world-leading multi-cancer early detection. MiRXES is a Singapore-headquartered biotechnology company that translates research discoveries to deliver world-leading multi-cancer early detection. We are Asia-centered, starting with Southeast Asia, and have global ambitions. We have research, development, manufacturing, and clinical diagnostic operations in Singapore, USA, Japan, …

Careers Read More »

MiRXES announces appointment of Dan Headon as Senior Vice President, Marketing

NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES announces appointment of Dan Headon as Senior Vice President, Marketing SINGAPORE, 15 November 2021 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered disease early detection tests, announced today the appointment of Mr. Dan HEADON as Senior Vice …

MiRXES announces appointment of Dan Headon as Senior Vice President, Marketing Read More »

MiRXES enters Hong Kong led by newly appointed Managing Director, Martin Law

NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES enters Hong Kong led by newly appointed Managing Director, Martin Law SINGAPORE / HONG KONG, 15 February 2022 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered cancer early detection tests, announced today the set-up of its Hong …

MiRXES enters Hong Kong led by newly appointed Managing Director, Martin Law Read More »

MiRXES Welcomes Professor Tony Mok to Scientific Advisory Board

NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES Welcomes Professor Tony Mok to Scientific Advisory Board SINGAPORE, 12 April 2022 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company focused on improving and saving lives with miRNA-powered cancer early detection tests, announced today the appointment of Professor Tony Mok, a world-renowned medical oncologist, to …

MiRXES Welcomes Professor Tony Mok to Scientific Advisory Board Read More »

Yayasan MENDAKI and MiRXES announce SG$140,000 MENDAKI – MiRXES scholarship scheme for undergraduate and post-graduate students

NEWSROOM Stay current with MiRXES Newsroom > Media Releases Yayasan MENDAKI and MiRXES announce SG$140,000 MENDAKI – MiRXES scholarship scheme for undergraduate and post-graduate students SINGAPORE, 23 October 2021 – Yayasan MENDAKI (“MENDAKI”) and MiRXES Pte Ltd (“MiRXES”), a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered disease early detection tests, are …

Yayasan MENDAKI and MiRXES announce SG$140,000 MENDAKI – MiRXES scholarship scheme for undergraduate and post-graduate students Read More »

MiRXES appoints Cher Hwa Teo as Senior Vice President, Health Innovation Delivery and Chief of Staff

NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES appoints Cher Hwa Teo as Senior Vice President, Health Innovation Delivery and Chief of Staff SINGAPORE, 1 October 2021 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered disease early detection tests, announced today the appointment of Mr. …

MiRXES appoints Cher Hwa Teo as Senior Vice President, Health Innovation Delivery and Chief of Staff Read More »

MiRXES Board of Directors welcomes strategic investor Da Liu from CR-CP Life Science Fund to fast-track groundbreaking early cancer diagnostics

NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES Board of Directors welcomes strategic investor Da Liu from CR-CP Life Science Fund to fast-track groundbreaking early cancer diagnostics Board appointment coincides with an additional US$10 million capital injection into MiRXES from private equity CDG Capital and NHH Ventures SINGAPORE, 21 September 2021 – MiRXES …

MiRXES Board of Directors welcomes strategic investor Da Liu from CR-CP Life Science Fund to fast-track groundbreaking early cancer diagnostics Read More »

Scroll to Top